AdaptHealth (AHCO) Q3 2024 earnings summary

Executive summary

• Q3 2024 net revenue was $805.9 million, up 0.2% year-over-year, as sleep and respiratory growth offset diabetes declines.

• Net income for Q3 2024 was $22.9 million, reversing a net loss of $454.1 million in Q3 2023, which included a $511.9 million goodwill impairment.

• Adjusted EBITDA for Q3 2024 was $164.3 million (20.4% margin), up from $161.2 million (20.0% margin) in Q3 2023.

• Free cash flow for the nine months ended September 30, 2024, was $162.7 million, more than double the prior year period.

• Significant leadership and operational changes were made in the diabetes segment to address underperformance.

Financial highlights

• Net revenue for the nine months ended September 30, 2024, was $2.40 billion, up 2.7% year-over-year.

• Operating income for Q3 2024 was $63.5 million, compared to a loss of $461.0 million in Q3 2023.

• Free cash flow for Q3 2024 was $84.8 million, up from $21.7 million in Q3 2023.

• Basic and diluted EPS for Q3 2024 were $0.16 and $0.15, compared to $(3.37) and $(3.43) in Q3 2023.

• Cost of net revenue for Q3 2024 was $681.9 million (84.6% of revenue), down 1.7% year-over-year.

Outlook and guidance

• Full-year 2024 guidance updated: net revenue expected at $3.22–$3.26 billion, Adjusted EBITDA at $655–$675 million, and free cash flow at $175–$195 million.

• Revenue and EBITDA guidance were reduced due to diabetes performance, while free cash flow guidance increased.

• Management expects continued inflationary pressures on materials, labor, and transportation, with mitigation efforts focused on vendor negotiations and technology-driven efficiencies.

• The company believes operating cash flows, existing cash, and available credit will be sufficient to fund operations and growth strategies for at least the next twelve months.

• Cautious outlook for diabetes segment, with improvement expected over several quarters.